Intervention

BI 1356

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions1

Lead sponsors shown1

Clinical trials

5 shown

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugNCT00819091 · 2008-12-01

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background InclusiveNCT00800683 · 2008-12-01

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial DesignNCT00798161 · 2008-12-01

Japanese P III vs Voglibose and PlaceboNCT00654381 · 2008-04-01

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesNCT00622284 · 2008-02-01

Common conditions

Diabetes Mellitus, Type 25

Leading sponsors

Boehringer Ingelheim5

Trial status mix

COMPLETED5

Phase mix

PHASE35

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.